Inicio>>Signaling Pathways>> GPCR/G protein>> LPL Receptor>>Sonepcizumab

Sonepcizumab (Synonyms: LT 1009; Anti-Human S1P Recombinant Antibody)

Catalog No.GC69926

Sonepcizumab (LT 1009) es un anticuerpo monoclonal completamente humanizado contra S1P. Sonepcizumab tiene potencial para la investigación de carcinoma renal metastásico (mRCC).

Products are for research use only. Not for human use. We do not sell to patients.

Sonepcizumab Chemical Structure

Cas No.: 1031360-18-5

Tamaño Precio Disponibilidad Cantidad
5mg
936,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Chemical Properties Product Documents

Reseñas

Review for Sonepcizumab

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Sonepcizumab

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.